Prasco to distribute authorized generic treatment for tumor disorder
CINCINNATI — Prasco Labs has signed a deal with WellSpring Pharmaceutical Corp. to market an authorized generic version of a drug for a rare tumor disorder.
The company announced Wednesday the distribution and supply agreement for phenoxybenzamine hydrochloride capsules in the 10 mg strength for pheochromocytoma, an adrenal gland tumor disorder. The drug is used to control episodes of hypertension and sweating associated with the disorder.
The drug is an authorized generic version of WellSpring’s Dibenzyline. An authorized generic is a branded drug marketed under its generic name at a discount, usually under a deal between the branded drug’s manufacturer and a third-party company.
Publix posts 6.1% gain in first-quarter sales
LAKELAND, Fla. — Publix on Wednesday posted first-quarter sales of $7.5 billion, representing a 6.1% increase. The Easter holiday in the first quarter of 2013, which was in the second quarter of 2012, increased sales by approximately 1.3%, the grocer noted.
Comparable-store sales for the first quarter of 2013 increased 3.9%.
“I’m very pleased that our strong operating performance and improvements in the stock market resulted in a significant increase in our stock price,” stated Publix CEO Ed Crenshaw. “I want to thank our associates — the owners of Publix — for continuing to make us a leader in our industry.”
Effective May 1, Publix’s stock price increased from $23.20 per share to $26.90 per share. Publix stock is not publicly traded and is made available for sale only to current Publix associates and members of its board of directors.
Actavis to acquire rights to Valeant drug
PARSIPPANY, N.J. — Drug maker Actavis has acquired rights to a treatment for an experimental bacterial vaginosis from Valeant Pharmaceuticals International for about $55 million, the drug makers said Wednesday.
Actavis Specialty Brands’ acquisition of Valeant’s metronidazole vaginal gel is in the 1.3% strength. The deal includes an upfront payment, milestone payments and royalties for the first three years after the drug is commercialized. Actavis hopes to market the drug as early as the middle of next year.
"We believe this compound has significant potential to help patients in need of new treatment," Valeant EVP and company group chairman Laizer Kornwasser said. "We are very pleased to acquire the rights to an additional potential product that further expands our Women’s Health development pipeline and look forward to the ultimate launch of the product."
Are you a nurse practitioner or physician’s assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.